SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Odyssey Oil & Energy (OTCBB: OOGI) Trading at $0.56, Up $0.06. Today announced that the Algae Bio-fuels / Carbon Capture pilot plant at the Boschoek smelter is running and has successfully completed a variety of tests. The Algae is growing rapidly and being harvested on a regular basis thereby meeting the goals of carbon capture and creating lipids to be converted into bio-fuel.
ALG Western Oil (Pty) Ltd, a subsidiary of Odyssey, is currently operating in a joint venture with Xstrata Alloys, a subsidiary of Xstrata Plc (LSE: XTA), the world's largest producer of ferrochrome in a project at one of Xstrata's ferrochrome smelters near Rustenburg in South Africa to capture and sequestrate the carbon dioxide emissions thereby creating carbon credits.
Currently all the carbon monoxide from the ferrochrome smelters is flared to carbon dioxide and released into the atmosphere.
The current phase is the growing of a selected algae strain in photo bio-reactors, utilizing the carbon dioxide (CO2) flue gas coming from the exhausts of the generators, (with the aid of sunlight and some nutrients, through the process of photosynthesis) to sequestrate the environmentally harmful CO2 emissions and produce high value compounds like vegetable oil which can be used directly as a bio fuel instead of diesel and or jet fuel, carbohydrates and protein to be used in the animal feed industry and the release of oxygen back into the atmosphere.
What They Do: Odyssey Oil and Energy (OOGI) is a green technology company with two separate operating entities, one deals in carbon sequestration and one deals in advanced battery technology.
ALG Bio Oil Ltd., is a wholly owned subsidiary that focuses on the bio-fixation of carbon dioxide emissions from various industrial processes to produce carbon neutral products and the release of oxygen into the atmosphere.
ALG is currently operating in a joint venture with Xstrata PLC the world’s largest producer of ferrochrome in a project at one of Xstrata's Ferro-chrome smelters near Rustenburg in South Africa to capture and sequestrate the CO2 off gas emissions. Currently all the (CO) carbon monoxide off gas from the ferrochrome smelters is flared to (CO2) carbon dioxide and released into the atmosphere.
H-Power (Pty) Ltd., is 51% owned by OOGI, it has advanced battery technology and know-how to jumpstart a new wave of battery knowledge globally with registered patent rights. This innovation not only revolutionizes the functionality of conventional battery power but also provides for novel methods of using battery power with the added potential of reducing CO2 emissions and thereby also reducing conventional energy’s overall carbon footprint.
Agilent Technologies Inc. (NYSE: A) and Varian, Inc. (Nasdaq: VARI) Trading at $50.60, Up $11.40. Today announced that they have signed a definitive agreement for the acquisition by Agilent of Varian, a leading worldwide supplier of scientific instrumentation and associated consumables for life science and applied market applications. Agilent will pay $52 cash per share of common stock for Varian in a transaction that represents a premium of approximately 35% to Varian’s closing price on July 24, 2009. Both Agilent’s and Varian’s Board of Directors have unanimously approved the all-cash offer.
What They Do: Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science, environmental, energy, and applied research and other applications.
Ariad Pharmaceuticals (Nasdaq: ARIA) Trading at $2.21, Up $0.48. Today announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. The study results provide initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major hematology meeting to be held later this year.
Thirty-two patients have been enrolled to date in this trial in six dosing groups (once daily oral dosing) at five medical centers in the United States; 28 of the patients have resistant and refractory CML or Ph+ ALL. All patients have previously been treated with the currently available first- and second-generation targeted therapies for CML and in most instances, other investigational agents as well. The patients with CML and Ph+ALL enrolled in this study only had very limited treatment options available to them: stem cell transplants, conventional palliative chemotherapy or investigational agents. The study commenced patient enrollment in the second quarter of 2008 and will continue enrolling patients until approximately 50 patients have been enrolled. Dose-escalation will continue until dose-limiting toxicity is observed.
What They Do: ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SCR web site. SCR has been compensated three thousand five hundred dollars by a third party GreenHorseshoe for its services with regards to Odyssey Energy and Oil.
